Metraipolis › archive › dc_790016dfc8e1
Clinical Outcomes and Healthcare Resource Utilization of Ceftolozane/Tazobactam in Vulnerable Patient Populations — Europe PMC PMID:41750477
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41750477
- DOI
- 10.3390/antibiotics15020179
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T01:45:45.594Z
- SHA-256 of the archived text
2bd04023c7e20f5db4b72fc06cfafe0cdf3d501514724c57a3724639ebdc4f07- Stable URL of this page
https://metraipolis.com/documento/dc_790016dfc8e1
How to cite
Clinical Outcomes and Healthcare Resource Utilization of Ceftolozane/Tazobactam in Vulnerable Patient Populations — Europe PMC PMID:41750477 — Europe PMC (en), https://europepmc.org/article/MED/41750477 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_790016dfc8e1 (Metraipolis archive dc_790016dfc8e1, sha256 2bd04023c7e20f5db4b72fc06cfafe0cdf3d501514724c57a3724639ebdc4f07)
BibTeX
@misc{dc790016dfc8e1,
title = {Clinical Outcomes and Healthcare Resource Utilization of Ceftolozane/Tazobactam in Vulnerable Patient Populations — Europe PMC PMID:41750477},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41750477},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_790016dfc8e1; sha256 2bd04023c7e20f5db4b72fc06cfafe0cdf3d501514724c57a3724639ebdc4f07},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41750477. Agents can read the archived copy with the MCP tool read_document.